When
Johnson & Johnson
reports its earnings on Tuesday morning, one big question will be on investors’ minds: What’s going on with the plan to make the consumer-health business into a separate company?
Johnson & Johnson
(ticker: JNJ) is the last of the big pharma conglomerates. As peers like
Eli Lilly
(LLY),
Pfizer
(PFE), and
GSK
(
GSK
) have stripped away all but their core biopharma businesses, Johnson & Johnson had stuck firm to the old model, combining a huge consumer-health business, a large medical-devices division, and a biopharma business.
